Mayne looks to get out of US generic drug pricing antitrust case
MLex Summary: Mayne Pharma moved to dismiss US antitrust claims over generic pharmaceutical pricing, saying the factual allegations against it are practically nonexistent. Mayne argued that the plaintiffs have pleaded no...To view the full article, register now.
Already a subscriber? Click here to view full article